Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• in which R1 is selected from a group of formula (i) or (ii)
• Group of formula (i)
• where P1 is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, a benzofused heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a pyridofused heterocyclic ring containing 1 to 3 nitrogen atoms;
• Ra is halogen, C1-6alkyl, C3-6cycloalkyl, CF3, C1-6alkoxy, OCF3, hydroxy, cyano, nitro, hydroxyC1-6alkyl, COC1-6alkyl, CO2R5, SO2R5, NR5R6, CONR5R6, and SO2NR5R6 where R5 and R6 are independently hydrogen or C1-16alkyl;
• n is 0, 1, 2 or 3;
• Group of formula (ii)
• in which P2 and P3 are independently as defined for P1 above;
• Rb and Rc are independently as defined for Ra above;
• p and q are independently as defined for n above;
• L is a single bond or NH;
• R2 is hydrogen or together with the group R3 forms a further group —CH═CH— or —(CR7R8)2— where R7 and R8 are independently hydrogen or C1-6alkyl;
• R3 is hydrogen or together with R2 forms a further group as defined above;
• Y is N or CH;
• X is N or CH;
• R4 is hydrogen or C1-6alkyl.